HMGB2 and central nervous system cancer: In public databases, rare (0.39%) gene mutations were observed in HMGB2 [18,19,20,30], and only 2% of the cases presented gene amplification (N = 1) or deep deletion (N = 14), all but one observed in the TCGA dataset labeled “lower grade gliomas” [18,19].